Navigation Links
Uroplasty Announces Addition of Robert Kill to its Board of Directors
Date:12/8/2010

MINNEAPOLIS, Dec. 8, 2010 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the appointment of Mr. Robert (Rob) Kill to its Board of Directors.  Mr. Kill's appointment increases the membership on the Board to seven.

Mr. Kill (46) is the President, CEO and a Board member of Virtual Radiologic Corporation, a Minneapolis-based, high growth provider of teleradiology and technology solutions to radiology practices and hospitals throughout the United States.  Prior to joining Virtual Radiologic, Mr. Kill served as President of the Physicians Systems business at Misys Healthcare, a developer of healthcare software systems.  Earlier, he spent 10 years with Baxter Healthcare, where he held senior leadership positions in operations, marketing and sales.  He holds a B.A. in Economics from the University of Notre Dame.

"We are very pleased to have Rob join our Board at this key time at Uroplasty," said Patrick Maxwell, Chairman of the Board.  "His 19 years of experience with growing medical products and service companies will be extremely valuable to us as we execute our strategy to drive revenue growth and enhance valuation for our shareholders."

"I am excited to join Uroplasty's Board as the Company re-launches its Urgent PC Neuromodulation System in the U.S. for the treatment of overactive bladder," said Mr. Kill.  "I believe that my experience in a high growth environment will be of value to Uroplasty's Board and shareholders during this pivotal time in the Company's development."

David Kaysen, President and CEO of Uroplasty said, "Rob brought Virtual Radiologic public, growing it several fold in four years, and then sold the company in a private transaction.  As we roll out the re-launch plans for Urgent PC, and prepare for our growth, Rob's skills and expertise will be invaluable in dealing with the challenges and opportunities ahead of us."  

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140


EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
2. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
3. Uroplasty Reports Financial Results for the Second Quarter FY2011
4. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
5. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
6. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
7. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
8. Uroplasty Reports Results for Second Quarter FY2010
9. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
10. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
11. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a ... witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation ... educator interacting with countless women who had little knowledge of the female characters portrayed ...
(Date:1/20/2017)... ... ... biographical account following a man who went on to support his country and serve the ... Lynn Haven, Florida and at the age of 5, his family moved to Pensacola Florida. ... Navy and got married right out of boot camp. , He and his wife ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of ... three in Oklahoma City, and a devoted woman of faith. , “Becoming a parent ... the back of my mind for years, but actually doing it might have been a ...
(Date:1/20/2017)... ... 2017 , ... “The Land of More and More”: a brilliant story ... and shares the simple and achievable answer. “The Land of More and More” is ... Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
Breaking Medicine News(10 mins):